141 related articles for article (PubMed ID: 12206813)
1. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy.
Kinali M; Mercuri E; Main M; Muntoni F; Dubowitz V
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S169-74. PubMed ID: 12206813
[TBL] [Abstract][Full Text] [Related]
2. Remission of clinical signs in early duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy.
Dubowitz V; Kinali M; Main M; Mercuri E; Muntoni F
Eur J Paediatr Neurol; 2002; 6(3):153-9. PubMed ID: 12363102
[TBL] [Abstract][Full Text] [Related]
3. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
6. [Prednisolone treatment for Duchenne muscular dystrophy].
Shimomura H; Fujii T; Miyajima T; Kumada T; Kimura N; Oda N; Saito K
No To Hattatsu; 2011 Jan; 43(1):24-9. PubMed ID: 21400928
[TBL] [Abstract][Full Text] [Related]
7. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy.
Connolly AM; Zaidman CM; Golumbek PT; Cradock MM; Flanigan KM; Kuntz NL; Finkel RS; McDonald CM; Iannaccone ST; Anand P; Siener CA; Florence JM; Lowes LP; Alfano LN; Johnson LB; Nicorici A; Nelson LL; Mendell JR;
Muscle Nerve; 2019 Jun; 59(6):650-657. PubMed ID: 30706490
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
[TBL] [Abstract][Full Text] [Related]
9. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.
Connolly AM; Schierbecker J; Renna R; Florence J
Neuromuscul Disord; 2002 Dec; 12(10):917-25. PubMed ID: 12467746
[TBL] [Abstract][Full Text] [Related]
10. Prednisolone in Duchenne muscular dystrophy.
Rahman MM; Hannan MA; Mondol BA; Bhoumick NB; Haque A
Bangladesh Med Res Counc Bull; 2001 Apr; 27(1):38-42. PubMed ID: 11692899
[TBL] [Abstract][Full Text] [Related]
11. Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10 day on/10 day off prednisone regimen.
ten Dam K; de Groot IJ; Noordam C; van Alfen N; Hendriks JC; Sie LT
Neuromuscul Disord; 2012 Jun; 22(6):500-4. PubMed ID: 22390890
[TBL] [Abstract][Full Text] [Related]
12. Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy.
Wood CL; Cheetham TD; Hollingsworth KG; Guglieri M; Ailins-Sahun Y; Punniyakodi S; Mayhew A; Straub V
BMC Pediatr; 2019 Apr; 19(1):131. PubMed ID: 31023296
[TBL] [Abstract][Full Text] [Related]
13. Weekly oral prednisolone improves survival and strength in male mdx mice.
Keeling RM; Golumbek PT; Streif EM; Connolly AM
Muscle Nerve; 2007 Jan; 35(1):43-8. PubMed ID: 16969833
[TBL] [Abstract][Full Text] [Related]
14. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: A randomized, open-label trial.
Kochar GS; Sondhi V; Kabra SK; Yadav SL; Dwivedi SN; Gulati S
Muscle Nerve; 2022 Jan; 65(1):60-66. PubMed ID: 34617309
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid therapy for duchenne muscular dystrophy: improvement of psychomotor function.
Sato Y; Yamauchi A; Urano M; Kondo E; Saito K
Pediatr Neurol; 2014 Jan; 50(1):31-7. PubMed ID: 24138948
[TBL] [Abstract][Full Text] [Related]
16. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
[TBL] [Abstract][Full Text] [Related]
17. Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule.
Sansome A; Royston P; Dubowitz V
Neuromuscul Disord; 1993; 3(5-6):567-9. PubMed ID: 8186713
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
[TBL] [Abstract][Full Text] [Related]
19. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research.
Muntoni F; Fisher I; Morgan JE; Abraham D
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S162-5. PubMed ID: 12206811
[TBL] [Abstract][Full Text] [Related]
20. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
Bello L; Gordish-Dressman H; Morgenroth LP; Henricson EK; Duong T; Hoffman EP; Cnaan A; McDonald CM;
Neurology; 2015 Sep; 85(12):1048-55. PubMed ID: 26311750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
